NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) - Share Price
- Current share price for NSB : $0.054
NeuroScientific Biopharmaceuticals Ltd (NSB) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of biologics addressing unmet clinical need
NSB General Information +
| ASX Code | NSB |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 21 |
| NSB Share Price | $0.054 |
| Day High | $0.058 |
| Day Low | $0.052 |
| Last Close | $0.054 |
| NSB Share Price Movement | - ( No change ) |
Prices as at 16:40, 27 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
NeuroScientific Biopharmaceuticals Ltd (NSB) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from NeuroScientific Biopharmaceuticals Ltd (NSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
NeuroScientific Biopharmaceuticals Ltd (NSB) price-sensitive announcements
NSB - Quarterly Activities/Appendix 4C Cash Flow Report
NeuroScientific Biopharmaceuticals Limited’s Quarterly Activities Report and Appendix 4C f
NeuroScientific Biopharmaceuticals Ltd (NSB)
27 Oct 2026 | 9:08 AM
27 Oct 2026 | 9:08 AM
NSB - Leading CRO Appointed for Phase 2 Crohn's Trial
NeuroScientific Biopharmaceuticals Ltd announced on 1 October 2026 that it has appointed S
NeuroScientific Biopharmaceuticals Ltd (NSB)
1 Oct 2026 | 9:38 AM
1 Oct 2026 | 9:38 AM
NSB - 2026 Annual Report & Appendix 4E
NeuroScientific Biopharmaceuticals Limited (ASX: NSB) released its Appendix 4E and 2026 An
NeuroScientific Biopharmaceuticals Ltd (NSB)
25 Aug 2026 | 5:52 PM
25 Aug 2026 | 5:52 PM
NSB - Quarterly Activities/Appendix 4C Cash Flow Report
NeuroScientific Biopharmaceuticals Ltd announced positive developments in their ongoing ac
NeuroScientific Biopharmaceuticals Ltd (NSB)
28 Jul 2026 | 10:02 AM
28 Jul 2026 | 10:02 AM
NeuroScientific Biopharmaceuticals Ltd (NSB) Recent ASX Announcements
NSB Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$4.48 | -$1.30 | 5.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$1.85 | -$1.30 | -672.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | $0.32 | $0.20 | -129.70% | 27.70 | 0.00 | 0.00% | 0.0% |
NSB Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| CSL Limited (CSL) | $93,645M | 0.7309 | -0.4389 | 0.0602 | 12.0893 | 21.5458 | 20.3226 | 2.18% | 2.19% | 2.26% |
| Mesoblast Limited (MSB) | $2,323M | -0.4501 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 811.3636 | 0.00% | 0.00% | 0.00% |
| NeuroScientific Biopharmaceuticals Ltd (NSB) | $20M | 0.0556 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| PYC Therapeutics Limited (PYC) | $1,727M | -0.3971 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,373M | -1.3893 | 0.0000 | -0.5224 | 0.0000 | 151.1765 | 316.5025 | 0.00% | 0.00% | 0.00% |
NSB Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Robert Leslie McKenzie | Non-Executive Chairman, Non-Executive Director | 26 Jun 2025 |
| Mr Paul Damien John Fry | Non-Executive Director | 26 Jun 2025 |
| Dr Anton Uvarov | Non-Executive Director | 6 Sep 2017 |
| Mr Clarke Barlow | Non-Executive Director | 17 Nov 2023 |
| Dr Linda Friedland | Non-Executive Director | 18 Oct 2023 |
NeuroScientific Biopharmaceuticals Ltd (NSB) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Jun 2025 | UVAROV, Anton | Issued | Options | 1,000,000 | $0.000 | $100.000 |
| 27 Jun 2025 | BARLOW, Clarke | Issued | Options | 1,000,000 | $0.000 | $100.000 |
| 27 Jun 2025 | UVAROV, Anton | Issued | Direct Shares | 2,650,000 | $0.035 | $92,750.000 |
See all changes in directors' interest & trades for NeuroScientific Biopharmaceuticals Ltd (NSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NSB Management
| Name | Position |
|---|---|
| Christopher (Chris) Bryan Achurch | Company Secretary |
| Catherine Cole | Other Corporate Officer |
| Marian Sturm | Other Corporate Officer |
NSB Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in NeuroScientific Biopharmaceuticals Ltd (NSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 41,320,713 (10.60%) | Stum West Pty Ltd |
| 22,471,602 (5.77%) | Mr Paul Damien John Fry |
NSB Calendar of Events
| Date | Event |
|---|---|
| 24 August 2027 | Report (Annual) |
| 24 August 2027 | Report (Prelim) |
| 24 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
